Previous 10 |
home / stock / srtoy / srtoy news
2023-07-01 03:47:27 ET Summary Sartorius has been experiencing a demand decline since 2022. Sartorius serves a niche market, which gives it a strong moat. Sartorius benefits from the long-term tailwinds of its sector. We will review all the negative factors that are curren...
Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Conference Call January 26, 2023, 09:30 AM ET Company Participants Joachim Kreuzburg - CEO Rainer Lehmann - CFO, Member of Executive Board Conference Call Participants Odysseas Manesiotis - Berenberg Ma...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Sartorius Stedim Biotech S.A. press release (OTCPK:SRTOY): Q1 Non-GAAP EPS of €2.21. Revenue of €862.5M (+31.6% Y/Y). Underlying EBITDA margin 35.2%. Order intake was in line with expectations compared with the exceptionally strong prior-year quarter, reaching ...
Sartorius Stedim Biotech (OTCPK:SDMHF) closed the acquisition of Novasep's chromatography division, following approval by the U.S. Federal Trade Commission. The acquisition, which was announced in January 2021, was expected to be completed in H1 2021. The acquired business generated sale...
Sartorius Stedim Biotech S.A. (SDMHF): H1 GAAP EPS of €3.49.Revenue of €1.35B (+55.% Y/Y)Press Release For further details see: Sartorius Stedim Biotech S.A. reports H1 results
News, Short Squeeze, Breakout and More Instantly...
Sartorius Stedim Biotech S.A. - ADR Company Name:
SRTOY Stock Symbol:
OTCMKTS Market:
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...